Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 16;69(5):877-883.
doi: 10.1093/cid/ciy1143.

The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics

Johan Vekemans  1 , Fernando Gouvea-Reis  1 , Jerome H Kim  2 , Jean-Louis Excler  2 , Pierre R Smeesters  3   4   5   6 , Katherine L O'Brien  7 , Chris A Van Beneden  8 , Andrew C Steer  5   9   10 , Jonathan R Carapetis  11 , David C Kaslow  12
Affiliations

The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics

Johan Vekemans et al. Clin Infect Dis. .

Abstract

Group A Streptococcus (GAS) infections result in a considerable underappreciated burden of acute and chronic disease globally. A 2018 World Health Assembly resolution calls for better control and prevention. Providing guidance on global health research needs is an important World Health Organization (WHO) activity, influencing prioritization of investments. Here, the role, status, and directions in GAS vaccines research are discussed. WHO preferred product characteristics and a research and development technology roadmap, briefly presented, offer an actionable framework for vaccine development to regulatory and policy decision making, availability, and use. GAS vaccines should be considered for global prevention of the range of clinical manifestations and associated antibiotic use. Impediments related to antigen diversity, safety concerns, and the difficulty to establish vaccine efficacy against rheumatic heart disease are discussed. Demonstration of vaccine efficacy against pharyngitis and skin infections constitutes a key near-term strategic goal. Investments and collaborative partnerships to diversify and advance vaccine candidates are needed.

Keywords: group A Streptococcus; pharyngitis; rheumatic heart disease; vaccine.

PubMed Disclaimer

References

    1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685–94. - PubMed
    1. World Health Organization. 71st World Health Assembly. Rheumatic fever and rheumatic heart disease. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_25-en.pdf?ua=1 Accessed 5 September 2018.
    1. World Health Organization. Product development for vaccines advisory committee meeting—2014. Available at: http://www.who.int/immunization/research/meetings_workshops/pdvac_2014/en/ Accessed 5 September 2018.
    1. Osowicki J, Vekemans J, Kaslow DC, Friede MH, Kim JH, Steer AC. WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: report from a meeting held on 12–13 December 2016. Vaccine 2018; 36:3397–405. - PubMed
    1. World Health Organization. Immunization, vaccines, and biologicals. Available at: http://www.who.int/immunization/research/development/en/ Accessed 11 December 2018.

Substances